Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.
Taking everything into account, HRMY scores 8 out of 10 in our fundamental rating. HRMY was compared to 198 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! This makes HRMY very considerable for value and growth and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 14.56% | ||
ROE | 22.07% | ||
ROIC | 18.94% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 29.09% | ||
PM (TTM) | 20.36% | ||
GM | 78.06% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.25 | ||
Debt/FCF | 0.82 | ||
Altman-Z | 5.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.31 | ||
Quick Ratio | 3.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 12.23 | ||
Fwd PE | 7.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 8.41 | ||
EV/EBITDA | 6.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |